Phase 4 PALADIN Study with ILUVIEN® Published in Peer-Reviewed Journal Ophthalmology
February 23, 2022 08:00 ET
|
Alimera Sciences, Inc.
Best corrected visual acuity and central subfield thickness were significantly improved at 36 monthsILUVIEN treatment resulted in a 70.5% reduction in treatment burdenResults confirm that use of prior...
Alimera Sciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022, and Provide Corporate Update
February 17, 2022 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to...
Alimera Sciences Announces Launch of ILUVIEN® for Uveitis in Spain
February 07, 2022 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Sciences to Present at the MicroCap Rodeo Winter Wonderland Best Ideas Virtual Investor Conference
February 04, 2022 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Sciences to Participate in Upcoming January 2022 Investor Conferences
January 05, 2022 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to...
Alimera Sciences Welcomes Ophthalmic Strategic Consultant Erin Parsons to Its Board of Directors
December 01, 2021 07:30 ET
|
Alimera Sciences, Inc.
ATLANTA, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Sciences to Participate in Upcoming November 2021 Investor Conferences
November 09, 2021 13:16 ET
|
Alimera Sciences, Inc.
ATLANTA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Sciences Announces Third Quarter 2021 Financial Results
October 28, 2021 07:30 ET
|
Alimera Sciences, Inc.
Consolidated Net Revenue of $12.2 Million Down 2% vs. Third Quarter of 2020 and Up 14% vs. Second Quarter of 2021U.S. End User Demand up 15% vs. Third Quarter of 2020 and Second Quarter of 2021 ...
Alimera Sciences to Report Third Quarter 2021 Financial Results on Thursday, October 28, 2021, and Provide Corporate Update
October 21, 2021 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera) a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Recent 24-Month Real-World PALADIN Data Demonstrate the Ability of ILUVIEN® to Significantly Reduce Treatment Burden in Patients with Diabetic Macular Edema
October 13, 2021 08:00 ET
|
Alimera Sciences, Inc.
PALADIN Study Data Presented at the American Society of Retina Specialists Shows That Post-ILUVIEN, the Percentage of Eyes Receiving One Yearly Treatment or Less Increased 3.2-Fold Compared to...